Tocopherol

ApprovedSmall molecule

MM.D. Anderson Cancer Center

Tocopherol is one of 174 small molecule programs targeting Osteonecrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

173

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisActive, not recruiting

GlaucomaActive, not recruiting

MucositisActive, not recruiting

Chronic HepatitisActive, not recruiting

FibrosisActive, not recruiting

LymphedemaActive, not recruiting

OsteonecrosisPhase 3

Active, not recruiting

GlaucomaPhase 3

Active, not recruiting

MucositisPhase 2

Active, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

FibrosisPhase 2

Active, not recruiting

LymphedemaApproved

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

Tocopherol

MM.D. Anderson Cancer Center

Approved

1 2

PEG-Intron

Merck & Co.

Preclinical

43 3

Sovaldi

Gilead

Preclinical

34 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Medrol

Pfizer

Preclinical

1 9

Dasabuvir

AbbVie

Preclinical

7 10

SOF/VEL

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Recruiting

Lymphedema

NCT06494111

Q1 2033

Phase 2Recruiting

Fibrosis

NCT06912763

Clinical

Trials by Indication[1]

Lymphedema2 trials

Lipid Peroxidation and Options Antioxidant Therapy for Secondary Lymphedema of the Lower Extremities

Completed·RRyazan State Medical University·Phase 4·NCT04360889·120 enrolled

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06494111·295 enrolled

Fibrosis1 trial

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06912763·250 enrolled

Chronic Hepatitis1 trial

Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00119119·100 enrolled

Treatment1 trial

The Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT00188552·50 enrolled

Glaucoma1 trial

Impact of Oral Versatile Antioxidants on Glaucoma Progression

Completed·—·Phase 3·NCT01544192·60 enrolled

3 more indications

Mucositis1 trial

Tocopherol is a Novel Treatment for Cancer Related Mucositis

Withdrawn·HHadassah Medical Organization·Phase 2·NCT00162526·30 enrolled

End-Stage Renal Disease1 trial

The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis

Unknown status·KKing Abdulaziz University·Phase 3·NCT05350124·160 enrolled

Osteonecrosis1 trial

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

Enrolling by invitation·UUniversity of Washington·Phase 3·NCT03040778·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Tocopherol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tocopherol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tocopherol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MM.D. Anderson Cancer Center

Tocopherol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q1 2033

Trials by Indication[1]

Lymphedema2 trials

Fibrosis1 trial

Chronic Hepatitis1 trial

Treatment1 trial

Glaucoma1 trial

Mucositis1 trial

End-Stage Renal Disease1 trial

Osteonecrosis1 trial

References

Drug Info

Quick Facts

Related News